semaglutide for type 1 diabetes (Ozempic) can be beneficial to people with After treatment with semaglutide, newly

Supplementary information 41366_2025_1859_MOESM4_ESM.docx (download DOCX Network meta-analysis summary for the assessed gastrointestinal adverse events associated with GLP-1 receptor agonists in subjects with overweight and obesity Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made

Why are you saying this

Many insurance plans do not cover GLP-1 medications for type 1 diabetes, which can limit their use

Product quality in the unregulated research-chemical market is not guaranteed